Vigil Neuroscience (VIGL) Stock Forecast, Price Target & Predictions
VIGL Stock Forecast
Vigil Neuroscience stock forecast is as follows: an average price target of $11.00 (represents a 260.66% upside from VIGL’s last price of $3.05) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
VIGL Price Target
The average price target for Vigil Neuroscience (VIGL) is $11.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $11.00. This represents a potential 260.66% upside from VIGL's last price of $3.05.
VIGL Analyst Ratings
According to 3 Wall Street analysts, Vigil Neuroscience's rating consensus is 'Buy'. The analyst rating breakdown for VIGL stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vigil Neuroscience Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Paul Matteis | Stifel Nicolaus | $11.00 | $3.12 | 252.02% | 260.66% |
The latest Vigil Neuroscience stock forecast, released on Aug 15, 2024 by Paul Matteis from Stifel Nicolaus, set a price target of $11.00, which represents a 252.02% increase from the stock price at the time of the forecast ($3.12), and a 260.66% increase from VIGL last price ($3.05).
Vigil Neuroscience Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $11.00 |
| Last Closing Price | $3.05 | $3.05 | $3.05 |
| Upside/Downside | -100.00% | -100.00% | 260.66% |
In the current month, the average price target of Vigil Neuroscience stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vigil Neuroscience's last price of $3.05. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | Guggenheim | Buy | Buy | Hold |
| Jun 28, 2024 | Wedbush | Outperform | Outperform | Hold |
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Vigil Neuroscience's last stock rating was published by Guggenheim on Aug 14, 2024. The company gave VIGL a "Buy" rating, the same as its previous rate.
Vigil Neuroscience Financial Forecast
Vigil Neuroscience Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VIGL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Vigil Neuroscience EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict VIGL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vigil Neuroscience's previous annual EBITDA (undefined) of $NaN.
Vigil Neuroscience Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-18.80M | $-18.40M | $-18.12M | $-20.42M | $-22.11M | $-22.10M | $-22.33M |
| High Forecast | $-18.80M | $-18.40M | $-18.12M | $-17.16M | $-18.24M | $-22.10M | $-22.33M |
| Low Forecast | $-18.80M | $-18.40M | $-18.12M | $-23.28M | $-26.77M | $-22.10M | $-22.33M |
| Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VIGL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vigil Neuroscience SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VIGL last annual SG&A of $NaN (undefined).
Vigil Neuroscience EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.46 | $-0.45 | $-0.45 | $-0.50 | $-0.55 | $-0.54 | $-0.55 |
| High Forecast | $-0.46 | $-0.45 | $-0.45 | $-0.42 | $-0.45 | $-0.54 | $-0.55 |
| Low Forecast | $-0.46 | $-0.45 | $-0.45 | $-0.57 | $-0.66 | $-0.54 | $-0.55 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Vigil Neuroscience's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VIGL previous annual EPS of $NaN (undefined).
Vigil Neuroscience Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.57 | $18.00 | 1046.50% | Buy |
| PEPG | PepGen | $4.40 | $29.50 | 570.45% | Buy |
| MOLN | Molecular Partners | $5.20 | $29.00 | 457.69% | Buy |
| OPT | Opthea | $3.28 | $14.00 | 326.83% | Buy |
| CMPX | Compass Therapeutics | $1.37 | $5.00 | 264.96% | Buy |
| VIGL | Vigil Neuroscience | $3.05 | $11.00 | 260.66% | Buy |
| PRTC | PureTech Health | $21.70 | $57.00 | 162.67% | Buy |
| CGEM | Cullinan Oncology | $12.58 | $31.50 | 150.40% | Buy |
| TYRA | Tyra Biosciences | $15.87 | $31.75 | 100.06% | Buy |
| PHVS | Pharvaris | $20.50 | $39.67 | 93.51% | Buy |
| EWTX | Edgewise Therapeutics | $31.95 | $45.00 | 40.85% | Buy |
| THRD | Third Harmonic Bio | $11.62 | $16.15 | 38.98% | Buy |
| TRDA | Entrada Therapeutics | $17.93 | $20.00 | 11.54% | Buy |